Quantum Health Innovations Logo
501(c)(3) Advanced Biomedical Research Organization

Stem Cell Research. Validated. Published.

The next era of medicine is driven by data, not opinion. Quantum Health Innovations was founded to accelerate scientific discovery by integrating high-fidelity data, modern analytics, and next-generation research models—moving medicine from assumption to measurable truth. — Rakel Apodaca, Founder

Donate Now
See the Science
A nonprofit accelerating medicine forward

Quantum Health 501 (c)(3)

Stem Cell Research | Children First | Data A.I. Driven

A Real nonprofit Transparent with full disclosure on results

Research Highlight

Autism for Pediatrics

Stem Cell Pediatric Autism Research The first funding round focuses on Autism Spectrum Disorder Levels 1 and 2 in pediatric populations, utilizing minimally manipulated umbilical cord blood stem cells within a controlled clinical research framework. Study Structure     •    Level 1: Ages 3–7     •    40 patients     •    Budget: $950,000     •    Level 2: Ages 7–11     •    40 patients     •    Budget: $1.9 million Each cohort will undergo a 3-month clinical research period, with comprehensive laboratory baselines obtained before and after participation. Data collection will focus on biological markers, system-level response, and measurable physiological changes. Oversight & Publication The study will be led by Tracey Schaper, NP, serving as Lead Investigator. Results will be structured for publication and submission to the National Institutes of Health, with full publication targeted by Month 6.

Stem Cell Cancer Research

Cancer & NK Cell Comparative Research oncology, focusing on both cord blood stem cells and cord blood–derived isolated Natural Killer (NK) cells; Natural Killer Cells. Study Design     •    Total patients: 90     •    Cancer cohorts:     •    Breast cancer     •    Leukemia     •    Prostate cancer     •    30 patients per cohort This Phase 2 clinical research study will include three research arms, enabling direct comparison of tumor response, cancer marker changes, and biological signaling velocity. Comparative Objective Following initial results, a secondary Phase 2 study will replicate the protocol using NK cell–specific outcomes, allowing side-by-side comparison of:     •    Tumor reduction rates     •    Biomarker normalization     •    Speed of biological response Interim results will be published at Month 3, with final results at Month 6. Rakel Apodaca, Lead Investigator

Amyotrophic Lateral Sclerosis (ALS

Stem Cell ALS Research Amyotrophic Lateral Sclerosis (ALS) A 12-month longitudinal study involving 45 participants. Research Components     •    Minimally manipulated umbilical cord blood stem cells     •    Controlled quantum frequency exposure (constant parameters)     •    EBOO services     •    Serial laboratory and functional assessments Data & Regulatory Pathway Results will be tracked with time-stamped laboratory data to map biological response progression. NIH updates will be published at 3, 6, and 9 months, with final results at 12 months. Data will be formatted into SOPs supporting an FDA IND submission directly into Phase 2.

Amyotrophic Lateral Sclerosis (ALS)

Clinical Trials starting Spring of 2026

Lupus

Clinical Trials starting Spring of 2026

Traumatic Brain Injury (TBI)

Clinical Trials starting Spring of 2026

Why We're Different

A research plan that gives the world the evidence we been waiting for.

1
Data

Clinical Trials| IRB | IND

1. Regulatory-Ready Research Design Built for fast publication, replication, and approval.

2
2-3 Years

Fast Tracked Research

2. Minimally manipulated umbilical cord blood stem cells provided by Kalbio Biotechnology already under IND, ready for phase 2b submissions. less than 1 yr for initial publications, 2-3 years for phase 3 completions.

3
100% To Science

100% Transparent Funding

3. Direct-to-Research Funding Model Transparent allocation. No mission drifting.

Our Impact

Numbers that matter

14,000

Research patients treated with our research protocols to date.

65

Research Indications already with documented results

750

Successful Terminal Reversals (Cancer, ALS, Lupus, Leukemia, Lymes, Internal medicine)

100%

Funds Donations go towards Stem Cell Research.

Latest Updates

Latest from our research partners